I'm LongbridgeAI, I can summarize articles.In a report released today, Geoff Meacham from Citi maintained a Buy rating on Vertex Pharmaceuticals, with a price target of $585.00. Meacham covers the Healthcare sector, focusing on stocks such as Amgen, Vertex Pharmaceuticals, and Biogen. According to TipRanks, Meacham has an average return of 16.2% and a 59.75% success rate on recommended stocks. In addition to Citi, Vertex Pharmaceuticals also received a Buy from Barclays’s Eliana Merle in a report issued today. However, yesterday, Stifel Nicolaus maintained a Hold rating on Vertex Pharmaceuticals (NASDAQ: VRTX).
In a report released today, Geoff Meacham from Citi maintained a Buy rating on Vertex Pharmaceuticals, with a price target of $585.00.
Meacham covers the Healthcare sector, focusing on stocks such as Amgen, Vertex Pharmaceuticals, and Biogen. According to TipRanks, Meacham has an average return of 16.2% and a 59.75% success rate on recommended stocks.
In addition to Citi, Vertex Pharmaceuticals also received a Buy from Barclays’s Eliana Merle in a report issued today. However, yesterday, Stifel Nicolaus maintained a Hold rating on Vertex Pharmaceuticals (NASDAQ: VRTX).